Collectively, these results revealed that STAMBPL1 could transactivate PD‐L1 expression by facilitating nuclear translocation of RELA/p65 and STAMBPL1 inhibition might sensitize RCC to the anti‐PD‐1/PD‐L1 immunotherapy. This evidence concerns the gene STAMBPL1 and renal cell carcinoma.